Why hs-CRP doesn't tell the whole story: measuring the inflammation cycle

If you have ever asked your doctor to check your inflammation, they almost certainly ordered a single test: high-sensitivity C-reactive protein (hs-CRP).

For more than two decades, hs-CRP has served as modern medicine’s workhorse biomarker for systemic inflammatory risk. It is cheap, standardized across virtually every clinical laboratory in the world, and backed by landmark clinical trials such as JUPITER, in which rosuvastatin — which lowered LDL cholesterol by 50% and hs-CRP by 37% — reduced major cardiovascular events by about 44% in people with elevated hs-CRP but LDL in the reference range.¹

Yet, despite its clinical utility, relying on hs-CRP to evaluate your immune health comes with a fundamental catch:

hs-CRP cannot read an inflammatory response. It can only read the liver’s delayed reaction to one.

To truly understand chronic inflammation—why it persists, why it flares, and whether your body is actively quieting it—we have to look beyond static liver proteins. We need to measure more of the biological sequence: the inflammation cycle.

---

What hs-CRP actually measures (and why clinicians rely on it)

To understand what hs-CRP misses, we first have to appreciate what it does well.

C-reactive protein is not an immune cell, an antibody, or a cytokine. It is an acute-phase reactant manufactured by hepatocytes in the liver.

When tissues anywhere in the body experience distress, injury, or metabolic overload, local sentinel cells sound the alarm by releasing primary cytokines—chiefly Interleukin-6 (IL-6), along with Interleukin-1β (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α). When those circulating alarm signals reach the liver, they trigger hepatic gene expression to mass-produce acute-phase proteins, including CRP.

1. Local distress, injury or metabolic strain.
2. Alarm cytokines are released (IL-6, IL-1β, TNF-α).
3. The signals travel through circulation to the liver.
4. The liver changes its protein output and makes C-reactive protein (CRP).
5. CRP is detected in a blood sample 6–48 hours later.

Because CRP has a remarkably constant plasma half-life of approximately 19 hours, its concentration in your bloodstream at any given moment directly mirrors how intensely your liver is synthesizing it.² Clinicians categorize these levels using established cardiovascular risk tiers:

• < 1.0 mg/L: Low relative cardiovascular risk
• 1.0 – 3.0 mg/L: Average relative risk
• > 3.0 mg/L: High relative risk (or active transient inflammation)
• > 10.0 mg/L: Often reflects acute infection, trauma, or another acute inflammatory episode

This predictability makes hs-CRP a reliable, low-cost summary dosimeter of total-body acute-phase activity. But that summary statistic discards crucial biological dimensions.

---

A response that starts and then ends

In healthy human biology, inflammation is not a toxic state to be permanently suppressed. It is how the body responds to the world around it, from a virus to a hard workout, and a response starts and then ends.

• Activation starts a response. Pattern-recognition sensors (such as Toll-like receptors) detect microbial signatures or damage signals. Alarm cytokines (IL-1β, TNF-α, IL-6) spread the signal, chemokines call neutrophils and monocytes to the affected site, platelets and vascular barriers contain the area, and recruited cells clear what doesn’t belong.
• Resolution ends it. Pro-resolving programs halt further recruitment and switch macrophage behavior, spent neutrophils and debris are cleared through efferocytosis, and repair begins. Ending a response is an active, regulated process.

Read more in plain language in Inflammation, explained.

True health is not “zero inflammation.” True health is an inflammation cycle that initiates swiftly when needed, remains proportionate to the challenge, and—crucially—actively resolves when the job is done.

When you examine where conventional clinical biomarkers fall along this cycle, a stark pattern emerges: most routine inflammation tests cluster around the Alert stage, and none reads resolution.

---

Biomarker comparison across the cycle

---

The four critical blindspots of conventional testing

1. The resolution void

The most profound limitation of conventional testing is that nothing in routine clinical chemistry measures resolution.

For decades, medical textbooks incorrectly described resolution as passive—the simple dissipation of pro-inflammatory signals once an infection cleared. Landmark research over the past twenty years (pioneered by Charles Serhan and colleagues) revealed that resolution is an active, biochemically driven process.³ Cells must actively transcribe specific enzymes and receptors to produce specialized pro-resolving mediators (SPMs like resolvins, protectins, and maresins), halt neutrophil influx, and clear cellular debris through efferocytosis.

An hs-CRP result below 1.0 mg/L does not distinguish between these biological states:

• A quiescent, unperturbed immune system.
• An immune system that successfully engaged an active resolution program and returned to baseline.
• A smoldering, low-grade inflammatory state with stalled resolution that doesn’t push hs-CRP above the reference range.

2. Cell counts vs. cell states

Clinicians frequently inspect the Complete Blood Count (CBC) and derived ratios like the Neutrophil-to-Lymphocyte Ratio (NLR) to assess immune balance. Elevated NLR has substantial prognostic validation across oncology and cardiovascular cohorts.

However, counting immune cells tells you nothing about what those cells are actually doing.

A neutrophil count of 4,500 per microliter looks identical on a hematology analyzer whether those neutrophils are quiescent and circulating peacefully, or primed, activated, and transcribing cytotoxic enzymes. A CBC provides the census of the immune army; it cannot read the orders the soldiers are executing.

3. Substrate vs. process (the omega-3 analogy)

Many health-conscious individuals test their Omega-3 Index or Omega-6:Omega-3 ratio to assess their anti-inflammatory reserve. Long-chain omega-3 fatty acids (EPA and DHA) are vital because they serve as the direct chemical precursors for pro-resolving mediators.

However, testing fatty acid levels measures substrate availability, not process execution.

Think of it as inspecting your kitchen pantry: having shelves stocked with flour, oil, and spices confirms that you have the raw ingredients to cook a meal. It does not prove that anyone has turned on the stove. Whole-blood transcriptomics helps show whether the cellular machinery has actually begun cooking.

4. The flickering cytokine problem

Why not simply measure the alarm cytokines themselves, such as circulating IL-6 or TNF-α?

While direct cytokine assays exist on specialized panels, cytokines are biologically designed to act locally and vanish quickly. Circulating IL-6 has a half-life measured in minutes, fluctuates significantly based on circadian rhythms and sleep, surges up to 100-fold immediately following strenuous exercise, and binds to soluble receptors that distort immunoassays. Drawing blood for serum cytokines is often like trying to photograph lightning: you capture an unstable, fleeting flash of a signal designed to flicker.

By contrast, the gene expression programs triggered inside white blood cells integrate those cytokine signals over hours, organizing into more stable, coordinated networks — though these too shift with circadian timing, exercise, and acute illness.

---

How whole-blood transcriptomics itemizes the response

Rather than reading a single protein synthesized by the liver, the Inflammation Compass sequences the active messenger RNA (mRNA) inside circulating leukocytes from a single PAXgene blood sample.

By measuring the expression of thousands of genes and scoring them across curated pathways, the platform summarizes cellular activity as six readings, three for Activation and three for Resolution, plus an estimate of the immune cell mix from cellular deconvolution.

1. Activation phase (innate sensing and effector deployment)

Measures the transcriptional programs of danger detection (such as TLR pathways), inflammasome priming, IL-1 cytokine cascades, and neutrophil/monocyte activation. This tells you specifically which branches of the innate immune system are primed. It also includes the interferon (antiviral) pathways, which help distinguish an elevation driven by a transient viral challenge from chronic metabolic or myeloid inflammation.

2. Resolution phase (restrain, clear, repair)

The Resolution phase measures gene activity associated with restraining the response, clearing debris and supporting repair. Reading the Resolution readings alongside the Activation readings shows how these parts of the response sit together. Repeat blood samples show how each reading changes over time.

Cellular deconvolution: how many cells, and what they’re doing

By applying reference-based cellular deconvolution algorithms to whole-blood RNA sequencing data, the platform estimates the relative proportions of major leukocyte subsets (monocytes, neutrophils, CD4+ and CD8+ T cells, B cells, NK cells). This helps address the bulk-sequencing confound: is your inflammatory signal higher because you have more white blood cells, or because the same cells are transcribing pro-inflammatory programs more aggressively?

---

Bringing the pieces together: a complementary hierarchy

Transcriptomics does not render conventional blood work obsolete. Rather, it adds a cellular layer that helps put your traditional blood tests in context:

1. Metabolic Drivers (ApoB, HbA1c, Fasting Glucose): These tell you what is loading your vascular and metabolic system upstream.
2. Acute-Phase Reactants (hs-CRP, Ferritin): These provide an integrative, cost-effective summary echo of total-body acute-phase tone.
3. Whole-Blood Transcriptomics (Inflammation Compass): This itemizes the active cellular software—showing which programs are running in circulating immune cells, how the cell mix is shifting, and whether resolution programs are engaged.

By pairing your routine annual blood work with longitudinal transcriptomic monitoring, you and your healthcare provider can add cellular context to what a single protein number means—and follow more of the inflammation cycle.

---

Deepen your understanding

• Explore the Inflammation Compass Biomarkers: Review the pathways behind Activation and Resolution.
• Reserve your spot: Express interest in testing with at-home mobile phlebotomy when ordering opens.
• Information for Clinicians: Discover how longitudinal whole-blood RNA profiling enhances chronic care protocols.

Sources and further reading +

References

1. Ridker PM, et al. (2008) — Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 359(21):2195–2207. doi:10.1056/NEJMoa0807646. PMID 18997196.

2. Pepys MB, Hirschfield GM. (2003) — C-reactive protein: a critical update. J Clin Invest. 111(12):1805–1812. doi:10.1172/JCI18921. PMID 12813013.

3. Serhan CN, Savill J. (2005) — Resolution of inflammation: the beginning programs the end. Nat Immunol. 6(12):1191–1197. doi:10.1038/ni1276. PMID 16369558.

4. Nathan C, Ding A. (2010) — Nonresolving inflammation. Cell. 140(6):871–882. doi:10.1016/j.cell.2010.02.029. PMID 20303877.